Related Experiment Video
Updated: Jul 7, 2026

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat
Published on: June 17, 2016
Rat but not human interferons suppress hepatic oxidative drug metabolism in rats
P I Craig1, S J Williams, E Cantrill
1Department of Medicine, University of Sydney, Westmead Hospital, Australia.
Abstract:
An animal model suitable for in vivo studies of interferon-mediated suppression of hepatic oxidative drug metabolism has been developed. Rats were injected with either recombinant human interferon alpha A, recombinant human interferon gamma, recombinant rat interferon gamma, or vehicle and experiments were performed 24 h later. In some animals theophylline elimination was determined twice (10 days apart), once after interferon and once after vehicle. Theophylline clearance was also determined in the isolated perfused rat liver after pretreatment of animals with interferon or vehicle. Pretreatment of animals with rat interferon gamma significantly reduced theophylline clearance in the intact rat but neither human interferon alpha A nor human interferon gamma altered theophylline elimination in vivo. Similar results were observed in the isolated perfused rat liver. We then examined whether the effects of interferon on hepatic drug metabolism were generalized or confined to individual cytochrome P450 isozymes; androstenedione hydroxylation pathways were used as catalytic probes for individual cytochrome P450 isozymes. Rat interferon gamma (but not human interferon alpha A) decreased levels of total hepatic microsomal P450 and reduced androstenedione 16 beta-hydroxylation. The formation of three other hydroxylated androstenedione metabolites appeared reduced to a similar extent, although these changes were not significant. It is concluded that autologous but not heterologous interferons impair oxidative drug metabolism in the rat. The reduction of hepatic P450 produced by interferon may result from the suppression of multiple isozymes.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Drug toxicity: Idiosyncratic Reactions
Inhibitors of Viral Protein Synthesis

